Slide 1: Orion Half Year Report 1–6/2019
Orion Half Year Report 1–6/2019
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Highlights in January–June 2019
Highlights in January–June 2019
Slide 4: Marketing authorisation applications for darolutamide submitted in the main markets
Marketing authorisation applications for darolutamide submitted in the main markets 1 Marketing authorisation applications for the prostate cancer drug darolutamide 3 Net sales of Proprietary Products on previous year’s level. Easyhaler® and Simdax® submitted in the main markets showing strong sales
Slide 5: Key figures 1−6/2019
Key figures 1−6/2019 Net sales Operating profit Operating profit Cash flow per share margin before financial items* 493 107 22% 0.57 MEUR (493) MEUR (140) (28%) EUR (1.75) -23% -67% *) Comparison period cash flow per share before financial items includes both continuing and discontinued operations H
Slide 6: Development of net sales and operating profit
Development of net sales and operating profit Net sales Operating profit 493 16 3 493 140 2 7 5 2 4 7 3 19 4 9 4 107 51 51 49 46 27 (1) Product sales without sales margin and product mix change and exchange rate effect (2) Product sales margin and product mix change but without exchange rate effect
Slide 7: Geographical breakdown and development of net sales
Geographical breakdown and development of net sales 1-6/2019 MEUR 1-6/2019 1-6/2018 12% 180 -4% 30% 160 6% 140 120 +13% +13% -33% 100 80 60 +10% 34% 18% 40 20 0 Finland Scandinavia Other Europe North America ROW Half Year Report 1–6/2019 © Orion Corporation 17 July 2019
Slide 8: Net sales by business division
Net sales by business division 1−6/2019 1−6/2018 1-6/2019 MEUR -1% 250 230 232 6% 2% -5% 9% 200 188 178 36% 150 100 +18% +16% +11% 47% 46 39 50 30 26 9 8 Proprietary Products 0 Specialty Products Specialty Proprietary Animal Fermion CM* & Aniumal Health Products Products Health other Fermion CM* & o
Slide 9: Best-selling pharmaceuticals 1–6/2019
Best-selling pharmaceuticals 1–6/2019 Net sales Change vs . Indication (EUR million) 1−6/2018 1. Asthma, COPD 52 +20% 2. Parkinson’s disease 44 -27% 3. Acute heart failure 34 +17% 4. Intensive care sedative 34 -0% 5. Animal sedatives 21 +46% Rheumatoid arthritis, inflammatory 6. Biosimilars bowel di
Slide 10: Proprietary Products
Proprietary Products
Slide 11: Easyhaler® product family continued strong growth
Easyhaler® product family continued strong growth 1-6/2019 MEUR -27 % 3% 5% 70 +20% 60 25% 60 19% 52 +17 % 50 44 44 40 34 34 34 29 30 -47 % 20 11 10 6 19% 29% 0 Parkinson Easyhaler® Easyhaler® Parkinson Dexdor® Simdax® Precedex® franchise Dexdor® Simdax® Precedex® Other 1−6/2019 1−6/2018 Half Year R
Slide 12: Easyhaler® product family will be a key source of growth in the next few years
Easyhaler® product family will be a key source of growth in the next few years ● Budesonide-formoterol Easyhaler Sales, EUR million continued strong growth. 30 25 ● Product family total sales: +20% 20 15 ● Budesonide-formoterol Easyhaler: +33% 10 5 ● Salmeterol-fluticasone sales developed slower tha
Slide 13: Share of Orion's own sales in Parkinson growing
Share of Orion’s own sales in Parkinson growing Sales, EUR million 50 45 40 35 30 25 20 15 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2014 2015 2016 2017 2018 2019 Orion's own sales Parkinson (Stalevo®, Comtan®) deliveries to partners Half Year Report 1–6/2019 © Orion C
Slide 14: Sales of Dexdor intensive care sedative continued to grow – patent expired at the end of March
Sales of Dexdor intensive care sedative continued to grow – patent expired at the end of March Total value of European sedatives market: Sales, EUR million EUR 574 million (+3%) 20 12 % 18 16 14 12 % 12 65 % 10 8 6 11 % 4 2 0 Propofol 372 Meur (+4%) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
Slide 15: Specialty Products
Specialty Products GRION Building well-being
Slide 16: Specialty Products: price competition continued especially in Finland
Specialty Products: price competition continued especially in Finland Development of net sales Net sales by region Net sales by product 1−6/2019 1−6/2019 MEUR -3% 160 11% 8% 140 131 134 13% 120 24% 100 80 +25% -2% 57% 60 44 35 31 31 19% 40 68% 20 0 Finland Scandinavia Eastern Finland Generic drugs E
Slide 17: In Finland, price competition has led to a decline in the entire market of reference priced prescription drugs
In Finland, price competition has led to a decline in the entire market of reference priced prescription drugs The market of reference priced The sales of Orion's reference prescription drugs in Finland priced prescription drugs (1–6/2019) in Finland MEUR 216 (235) MEUR 56 (60) Market development Or
Slide 18: Orion is strong in home market Finland
Orion is strong in home market Finland Human pharma market in Finland 1−6/2019 Self-care Medicinal and non-medicinal products Reference priced products in hospital and pharmacy channels: EUR 1,376 million prescription Orion market share in EUR million drugs pharmacy 160 151 Orion 140 120 90 48 marke
Slide 19: Research and development
Research and development
Slide 20: Orion's key clinical drug development projects
Orion's key clinical drug development projects Project Indication Phase Registration Easyhaler® tiotropium COPD Bioequivalence study Darolutamide 1) Prostate cancer (nmCRPC) I II III Darolutamide 1) Prostate cancer (mHSPC) I II III ODM-109 (oral levosimendan) ALS I II III ODM-203 (targeted FGFR+VEGF
Slide 21: REFALS patient recruitment completed
REFALS patient recruitment completed 104 ALS centres in 14 countries • REFALS is an Orion study • 1st patient randomised July 2018 • Last patient randomisation in July 2019 – Last patient visit expected July 2020 – Study results in H2 2020 • Number of patients in the study 496 • Objective to demonst
Slide 22: Orion's key business targets in 2019
Orion's key business targets in 2019 1. Preparation for the commercialisation • Marketing authorisation of darolutamide. ARASENS trial (metastatic applications submitted in the main prostate cancer) continues in order to markets. expand the indication for the molecule. • Priority Review granted in t
Slide 23: Orion's key business targets in 2019
Orion's key business targets in 2019 3. Strengthening Orion’s position as the • Orion's sales volume in Finland most significant provider of generic drugs grew faster than the market. in Finland. Competitive product portfolio in Specialty Products and strengthening of product launches. 4. Accelerati
Slide 24: Orion's Sustainability Report for 2018 was published in May
Orion’s Sustainability Report for 2018 was published in May Read more: https://www.orion.fi/en/sustainability-report/
Slide 25: Key themes of corporate responsibility
Key themes of corporate responsibility Responsibility Ensure patient for the environment Ethics and safety and – production according Taking care of transparency of availability of to the principles Orionees operations medicines of sustainable development
Slide 26: This is how we are building well-being responsibly
This is how we are building well-being responsibly WE PRODUCE 1/3 OF THE GLOBAL SUPPLY OF ~200-300 NUMBER OF AUDITS CUSTOMER METHOTREXATE ANNUALLY COMPLAINTS IN 2018 56 (ppm) ORION’S FOCUS ON QUALITY THROUGHOUT THE LIFECYCLE PATIENT R&D RAW MANUFACTURING PACKING DELIVERY SALES PATIENT RECYCLING NEED
Slide 27: Outlook
Outlook
Slide 28: Outlook for 2019 remains unchanged
Outlook for 2019 remains unchanged Net sales Orion estimates that in 2019 net sales will be slightly higher than in 2018 (net sales in 2018 were EUR 977 million). The estimated net sales include the possible EUR 45 million milestone payment associated with the commercialisation of darolutamide. Oper
Slide 29: Orion calendar
Orion calendar Interim Report 1−9/2019 23/10/2019 Financial Statement Release for 2019 5/2/2020 AGM planned to be held 25/3/2020 Interim Report 1−3/2020 28/4/2020 Half-Year Report 1−6/2020 17/7/2020 Interim Report 1−9/2020 21/10/2020
Slide 30: Building well-being
Building well-being GRIoN Building well-being